Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
AOD 9604 With Retatrutide: Evidence, Safety, and UK Regulatory Status AOD 9604 with retatrutide is a combination increasingly discussed in weight-loss and body-composition circles, yet neither compound holds a Marketing Authorisation from the MHRA or EMA for use in the UK
DNA damage accumulation with age drives PARP hyperactivation, accelerating NAD+ depletion in a self-reinforcing cycle
Each of these options has its own mechanism, evidence base, and risk profile
(85 g) provides 833% of the DV (22,24)
This combination can optimize body composition rather than only weight loss
AOD-9604 does not affect IGF-1 because it lacks the receptor-binding domains necessary to activate growth hormone receptors
